Core Viewpoint - The company, Jiangsu Hualan Pharmaceutical Materials Co., Ltd., has announced a share repurchase plan using raised funds, self-owned funds, and self-raised funds, aiming to repurchase up to 1% of its shares through centralized bidding [1][2]. Summary by Sections Share Repurchase Plan - The company plans to use a total of no less than RMB 100 million and no more than RMB 200 million for the repurchase, with raised funds between RMB 30 million and RMB 60 million, and self-owned and self-raised funds also contributing [2]. - The repurchased shares will be used for cancellation to reduce registered capital and for employee stock ownership plans or equity incentives [2]. Price Adjustment - Following the implementation of the 2024 annual equity distribution, the maximum repurchase price has been adjusted from RMB 45.50 per share to RMB 34.84 per share, effective from July 14, 2025 [3]. Progress of Share Repurchase - As of August 20, 2025, the company has repurchased a total of 1,809,153 shares, accounting for 1.10% of the total share capital, with a maximum transaction price of RMB 33.959 per share and a minimum transaction price of RMB 28.700 per share [4][5]. Compliance and Future Actions - The company confirms that the share repurchase actions comply with relevant regulations and will continue to implement the repurchase plan based on market conditions, fulfilling disclosure obligations as required [6].
华兰股份: 关于使用超募资金、自有资金及自筹资金以集中竞价交易方式回购公司股份比例达1%的进展公告